《大行》花旗升創科(00669.HK)目標價至125元 重申「買入」評級
花旗發表報告指,創科實業(00669.HK)上半年業績創歷史新高,營業額增長7.1%,純利增長14.2%,略低於該行預測的17%。儘管如此,公司表示有信心在今年實現中至高單位數的收入增長,以及將EBIT利潤率由去年的8.7%擴大至10%的中期目標。
該行微調創科實業2025至2027年的盈利預測,並將目標價由110元上調至125元,預期自2026年起,由於更快贏得市場份額及行業增長正常化,收入將加速以高單位數增長。儘管該股今年可能再創業績新高,但今年以來表現欠佳,股價下跌7%,重申「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.